Presentation is loading. Please wait.

Presentation is loading. Please wait.

Acquired BRAF V600E Mutation as Resistant Mechanism after Treatment with Osimertinib  Chao-Chi Ho, MD, PhD, Wei-Yu Liao, MD, PhD, Chih-An Lin, Jin-Yuan.

Published byBenjamin Simon Modified over 6 years ago

Similar presentations

Presentation on theme: "Acquired BRAF V600E Mutation as Resistant Mechanism after Treatment with Osimertinib  Chao-Chi Ho, MD, PhD, Wei-Yu Liao, MD, PhD, Chih-An Lin, Jin-Yuan."— Presentation transcript:

1 Acquired BRAF V600E Mutation as Resistant Mechanism after Treatment with Osimertinib 
Chao-Chi Ho, MD, PhD, Wei-Yu Liao, MD, PhD, Chih-An Lin, Jin-Yuan Shih, MD, PhD, Chong-Jen Yu, MD, PhD, James Chih-Hsin Yang, MD, PhD  Journal of Thoracic Oncology  Volume 12, Issue 3, Pages (March 2017) DOI: /j.jtho Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

2 Figure 1 Cells grown from malignant pleural effusion of a patient at the time of progression while the patient was taking osimertinib, with an exon 19 deletion plus T70M plus BRAF V600E. (A) Morphologic features of the cell, including the attached confluent growth, are shown. (B) Genotyping of this cell was done with matrix-assisted laser desorption ionization–time of flight mass spectrometry and showed exon 19 Del plus T790M plus BRAF V600E. Journal of Thoracic Oncology  , DOI: ( /j.jtho ) Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

3 Figure 2 The effect of BRAF V600E inhibitor LGX818 (encorafenib) and T790M inhibitor AZD9291 (osimertinib) on EGFR pathway signaling in this exon 19 Del plus T790M plus BRAF V600E cell. Data depict Western blot analysis of various signaling proteins in the presence or absence of encorafenib and/or osimertinib. α-Tubulin was included as a control. No AKT phosphorylation was detected. LGX818 suppresses MEK signaling but had no significant effect on ERK phosphorylation. Combined LGX818 and AZD9291 had an effect on both MEK and ERK. H1975 cells harboring L858R plus T790M were used as a control. Journal of Thoracic Oncology  , DOI: ( /j.jtho ) Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

4 Figure 3 Defective colony formation of this cell after treatment with the BRAF V600E inhibitor LGX818 (encorafenib) and the T790M inhibitor AZD9291 (osimertinib). (A) Clonogenicity in a two-dimensional culture dish revealed defective colony formation after LGX818 treatment. Combined LGX818 and AZD9291 treatment had a more potent effect. (B) Colony numbers from (A) are illustrated graphically. Journal of Thoracic Oncology  , DOI: ( /j.jtho ) Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "Acquired BRAF V600E Mutation as Resistant Mechanism after Treatment with Osimertinib  Chao-Chi Ho, MD, PhD, Wei-Yu Liao, MD, PhD, Chih-An Lin, Jin-Yuan."

Similar presentations

Development of Renal Cysts after Crizotinib Treatment in Advanced ALK-Positive Non– Small-Cell Lung Cancer Yen-Ting Lin, MD, Yu-Fen Wang, MD, James Chih-Hsin.

Development of Renal Cysts after Crizotinib Treatment in Advanced ALK-Positive Non– Small-Cell Lung Cancer Yen-Ting Lin, MD, Yu-Fen Wang, MD, James Chih-Hsin.
Clinical and Testing Protocols for the Analysis of Epidermal Growth Factor Receptor Mutations in East Asian Patients with Non-small Cell Lung Cancer:

Clinical and Testing Protocols for the Analysis of Epidermal Growth Factor Receptor Mutations in East Asian Patients with Non-small Cell Lung Cancer:
Clinical and the Prognostic Characteristics of Lung Adenocarcinoma Patients with ROS1 Fusion in Comparison with Other Driver Mutations in East Asian Populations 

Clinical and the Prognostic Characteristics of Lung Adenocarcinoma Patients with ROS1 Fusion in Comparison with Other Driver Mutations in East Asian Populations 
Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.

Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.
Chee Khoon Lee, PhD, Johnathan Man, M. B. B. S

Chee Khoon Lee, PhD, Johnathan Man, M. B. B. S
Hironori Yoshida, MD, Young Hak Kim, MD  Journal of Thoracic Oncology 

Hironori Yoshida, MD, Young Hak Kim, MD  Journal of Thoracic Oncology 
EGFR Array: Uses in the Detection of Plasma EGFR Mutations in Non–Small Cell Lung Cancer Patients  Irene Yam, BSc, David Chi-Leung Lam, MBBS, PhD, Kaimin.

EGFR Array: Uses in the Detection of Plasma EGFR Mutations in Non–Small Cell Lung Cancer Patients  Irene Yam, BSc, David Chi-Leung Lam, MBBS, PhD, Kaimin.
A Higher Proportion of the EGFR T790M Mutation May Contribute to the Better Survival of Patients with Exon 19 Deletions Compared with Those with L858R 

A Higher Proportion of the EGFR T790M Mutation May Contribute to the Better Survival of Patients with Exon 19 Deletions Compared with Those with L858R 
Two Cases of Small Cell Lung Cancer Transformation from EGFR Mutant Adenocarcinoma During AZD9291 Treatment  Jun Soo Ham, MD, Seokhwi Kim, MD, Hee Kyung.

Two Cases of Small Cell Lung Cancer Transformation from EGFR Mutant Adenocarcinoma During AZD9291 Treatment  Jun Soo Ham, MD, Seokhwi Kim, MD, Hee Kyung.
Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib  Nobukazu Agatsuma, MD  Journal of.

Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib  Nobukazu Agatsuma, MD  Journal of.
Adrian G. Sacher, MD, Kimberly M. Komatsubara, MD, Geoffrey R

Adrian G. Sacher, MD, Kimberly M. Komatsubara, MD, Geoffrey R
T790M EGFR Mutation Detection in Cerebrospinal Fluid and Response to Osimertinib in a Lung Cancer Patient with Meningeal Carcinomatosis  Hugo Gortais,

T790M EGFR Mutation Detection in Cerebrospinal Fluid and Response to Osimertinib in a Lung Cancer Patient with Meningeal Carcinomatosis  Hugo Gortais,
Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib  Nobukazu Agatsuma, MD  Journal of.

Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib  Nobukazu Agatsuma, MD  Journal of.
Lung Adenocarcinoma Harboring EGFR T790M and In Trans C797S Responds to Combination Therapy of First- and Third-Generation EGFR TKIs and Shifts Allelic.

Lung Adenocarcinoma Harboring EGFR T790M and In Trans C797S Responds to Combination Therapy of First- and Third-Generation EGFR TKIs and Shifts Allelic.
Leptomeningeal Metastases in Patients with NSCLC with EGFR Mutations

Leptomeningeal Metastases in Patients with NSCLC with EGFR Mutations
Detection and Monitoring of the BRAF Mutation in Circulating Tumor Cells and Circulating Tumor DNA in BRAF-Mutated Lung Adenocarcinoma  Nicolas Guibert,

Detection and Monitoring of the BRAF Mutation in Circulating Tumor Cells and Circulating Tumor DNA in BRAF-Mutated Lung Adenocarcinoma  Nicolas Guibert,
Rapid Acquisition of T790M Mutation after Treatment with Afatinib in an NSCLC Patient Harboring EGFR Exon 20 S768I Mutation  Alessandro Russo, MD, Tindara.

Rapid Acquisition of T790M Mutation after Treatment with Afatinib in an NSCLC Patient Harboring EGFR Exon 20 S768I Mutation  Alessandro Russo, MD, Tindara.
Acquired BRAF V600E Mutation as Resistant Mechanism after Treatment with Third- Generation EGFR Tyrosine Kinase Inhibitor  Alessandra Bearz, MD, Elisa.

Acquired BRAF V600E Mutation as Resistant Mechanism after Treatment with Third- Generation EGFR Tyrosine Kinase Inhibitor  Alessandra Bearz, MD, Elisa.
T790M EGFR Mutation Detection in Cerebrospinal Fluid and Response to Osimertinib in a Lung Cancer Patient with Meningeal Carcinomatosis  Hugo Gortais,

T790M EGFR Mutation Detection in Cerebrospinal Fluid and Response to Osimertinib in a Lung Cancer Patient with Meningeal Carcinomatosis  Hugo Gortais,
Epidermal Growth Factor Receptor Mutations in Small Cell Lung Cancer: A Brief Report  Tsu-Hui Shiao, MD, Yih-Leong Chang, MD, Chong-Jen Yu, MD, PhD, Yeun-Chung.

Epidermal Growth Factor Receptor Mutations in Small Cell Lung Cancer: A Brief Report  Tsu-Hui Shiao, MD, Yih-Leong Chang, MD, Chong-Jen Yu, MD, PhD, Yeun-Chung.

Similar presentations

Ads by Google